Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Conjugative plasmids in Klebsiella pneumoniae are autonomous, extrachromosomal DNA elements that serve as primary vehicles for the horizontal dissemination of antibiotic resistance genes. These plasmids are particularly notorious for carrying carbapenemase genes, such as blaKPC and blaNDM, which render infections nearly untreatable with standard-of-care beta-lactam antibiotics (Wyres & Holt, 2018). They utilize a Type IV secretion system to physically transfer genetic material between bacterial cells, often crossing species boundaries within the Enterobacteriaceae family (Navas-Tienda et al., 2024). In addition to resistance, these plasmids frequently harbor virulence factors and heavy metal resistance genes, providing a significant fitness advantage to the host bacterium in hospital settings. Therapeutic strategies targeting these plasmids, such as plasmid-curing agents or conjugation inhibitors, aim to disarm the bacteria rather than kill them directly, potentially reducing the selective pressure for new resistance mechanisms (Buckner et al., 2018). Emerging technologies like CRISPR-Cas9 are being explored to specifically eliminate these plasmids from bacterial populations, offering a precision medicine approach to managing multidrug-resistant Klebsiella infections.
Inhibition of plasmid replication, interference with the Type IV secretion system (T4SS), or targeted degradation of plasmid DNA via CRISPR-Cas systems.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Conjugative resistance plasmids of Klebsiella pneumoniae.